Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Onboarding businesses in all of the Americas could quickly snowball as more and more companies join the NextPlat initiative of new e-commerce profitability and success stories about the program emerge."
https://web3mediawire.com/nextplat-corp-nasdaq-nxpl-celebrates-great-day-in-miami-with-more-on-the-way/
Thanks
U 2 Gedi
In my case that is certainly correct. No dry powder to average down and no interest in selling at a loss.
$RXMD
Using this board as a small sample size, seems like most here are just sitting on the sidelines holding their current shares and not adding. Thus “No interest”
In this case we have both!
Gedi, with due respect, you are beating a dead horse. You and I can't change what is.
$RXMD
Actually a big distinction. Lack of interest vs unknown to the investment community is a huge difference.
Gedi, you're arguing a distinction without a difference. Whether the stock is unknown, and therefore leading to a lack of interest, or the stock is known, and someone doesn't want to buy; it equates to the same outcome of no market interest.
It definitely is true here
Again, not necessarily. The spread can be wide on certain stocks for a variety of reasons. Market volatility, market makers, a stock that is unknown to the investment community etc. One person can claim lack of interest while another may say the company is relatively unknown. Who’s right and who’s wrong. In this case none of us can say for sure.
In the case of RXMD, it is very true, hence the avg daily volume.
That's not always true my friend.
The reason for the spread and large drop is because there is no market interest in this stock.
James, I don't know what news that will come out regarding this company; good or bad. I do know one thing for certain, I won't be chasing it.
Just noticed that myself
Looks like NXPL getting some buying all of a sudden.
There's a large B/A spread. That's the reason for the 20% drop. Nothing more.
Yep, It will be like Sham chasing Secretariat.
Yes but when we get news, you will be left chasing share price, it works both ways.
Yep, when 500 shares results in a 20% drop in price, it generally doesn't bode well for you, if liquidity is a concern.
Do you see this as something good for TSOI?
I believe in you sf. Thank you for all you do.
No need to be sarcastic. It has been preplanned.
Effective July 1, 2023, Progressive Care's current CFO, Cecile Munnik, will become a fulltime employee of NextPlat. Just about 30 days out.
https://contracts.justia.com/companies/progressive-care-inc-14070/contract/260234/
She personally purchased 3522 shares of the company's common stock on the open market about 10 days ago.
No problem
Form 3 out - Pamela Roberts, COO beneficially owns 3,522 shares opf RXMD.
That's actually not true
Been super quiet for over 3 years
All sounds great for a company not named progressive care
Fernandez and Barreto invested tens of millions of their own dollars in NextPlat and became the company's CEO and Director. Ellenoff invested 0 of his own dollars in the company and was appointed as Vice Chairman and Chief Business Development Strategist and given millions of shares. Why?
https://ir.nextplat.com/news-events/press-releases/detail/82/orbsat-corp-expands-focus-on-e-commerce-with-appointments
Mr. Fernandez, said, "David Phipps and I are honored and excited to welcome Douglas at what is a critical inflection point in our corporate development. Supported by over $14 million in new growth capital to strengthen the balance sheet and significant second quarter revenue growth, we intend to further capitalize on the strength and scale of our online business model. The addition of Douglas Ellenoff is an important initial step in our transition to becoming a global e-commerce platform company with revenue opportunities across various high-growth sectors of the e-commerce space."
All is planned. NextPlat is the ONLY company where he's holding a position other than his own companies. His resume makes it no more need to speculate why a prominent investor like him would have decided to join NextPlat. There can be only one reason.
"Douglas S. Ellenoff, a member of Ellenoff Grossman & Schole LLP since its founding in 1992, is a corporate and securities attorney with a focus on business transactions and corporate financings. The Firm, which consists of nearly 80 lawyers, has established itself as a leader in various capital market initiatives, such as, Crowdfunding, SPACs, PIPEs and Registered Direct offerings. He is also Chairman and Co-Founder of iDisclose, an online application for entrepreneurs and small businesses. iDisclose may be deemed to be an ancillary business of the law firm, which indirectly through an investment holding company, has an ownership interest in the business opportunity.
During his career, he has represented numerous entreprenuers, broker-dealers, investor groups and many corporations involved in the capital formation process. In the last few years alone, he has been involved at various stages in numerous registered public offerings, including 100 financings and, with other members of his firm, over 500 private placements into public companies (see PIPEs and Venture Capital), representing either the issuers of those securities or the registered broker-dealers acting as placement agent. Along with other members of his Firm, Mr. Ellenoff has been involved at various stages with 125 registered blind pool offerings (commonly referred to as "SPACs") and 25 sizable SPACquisitions (the M&A component). With respect to Crowdfunding, he is actively engaged with clients (funding portals, broker-dealers, technology solution providers, software developers, investors and entrepreneurs)-- he has been to both the SEC and FINRA numerous times to discuss the proposed rules. He also provides counsel with regard to their respective ongoing (SEC, AMEX and NASD) regulatory compliance. Mr. Ellenoff has represented public companies in connection with their initial public offerings, secondary public offerings and regulatory compliance."
https://www.linkedin.com/in/douglas-ellenoff-588b682/
With the Memorial Day weekend coming up. It will be super quiet until next week
VP it tells me that only a handful of people are privy to this. That means we are either in a great position as share holders, or we are screwed. I like our chances. Plus the SP is holding up so far.
$1000 in volume tells me that either nobody believes the current theory or that the dangling carrot has caused people to wait for something of substance. You would think with all this Blockbuster speculation there would be more than two hundred in volume.
What will NextPlat do after it spins off Telesat/Satcom? Ellenoff will be the one introducing new partnerships and other opportunities to NextPlat. "12 or more potential Business Transactions per year". See his 3-year employment agreement filed on August 24, 2021:
"(B) Options to purchase 750,000 Shares shall vest at the rate of 250,000 per year on each of the first three anniversaries of the Effective Date if the following vesting conditions were satisfied during the prior year: Mr. Ellenoff shall have introduced the Corporation to twelve (12) or more potential Business Transactions (defined below) intended to expand the business of the Corporation during the preceding year, one of which the Chief Executive Officer (“CEO”) determined was sufficiently of interest to the Corporation to cause an in person or virtual meeting with the relevant parties. Potential Business Transactions could consist of US-based or international license, distribution, joint venture, partnership, acquisition, merger, asset purchase, or capital stock exchange, opportunities."
https://www.sec.gov/Archives/edgar/data/1058307/000149315222002407/ex10-1.htm
What is a Spin-Off?
A spin-off refers to the formation of an independent entity, in which shares of the subsidiary are distributed among the shareholders of the parent company. The existing shareholders receive shares in proportion to their original ownership percentage in the company, i.e. on a pro rata basis, and in the form of a non-cash special dividend. Therefore, the number of shares received by an existing shareholder is directly a function of the number of shares the shareholder held in the parent company.
https://www.wallstreetprep.com/knowledge/spin-off/
Currently, NextPlat's revenue is 100% from Global Telesat and Orbital Satcom. What can happen to NXPL stock price after spinoff? Will it go to zero? LOL, it's very obvious that NextPlat will acquire another major business (such as Progressive Care) so the stock price of NXPL will remain stable or even go higher because of much higher revenue from RXMD. At the same time, all those $8M investment from NextPlat (potentially up to $11M in order to reach 50% control) and $6M from Phillip Frost will all go into the expansion of the newly created healthcare biz centered around Progressive. The higher the stock price of RXMD, the better it will be for the new owners and for all of us after spinoff as NextPlat indicated in its most recent PR.
https://ir.nextplat.com/news-events/press-releases/detail/103/nextplat-strengthens-ties-to-progressive-care-inc
Nobody buying the latest unshared "discovery" regarding Alibaba and silent period until July 20th , nor was there any significant buying of RXMD shares today.
Share selling of both of Fernandez's "wizardry" companies is nearly double the buy volume. And partner NXPL still remains under NASDAQ market non-compliance: Status Alert - Deficient
RXMD
BUYS: 900
SELLS: 1,637
NXPL
BUYS: 3,817
SELLS: 9,916
Both NXPL & RXMD closed red as usual. Last weeks fireworks was not a fluke, short sellers may be in control here.
Followers
|
745
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
194638
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |